Members |
targetComponentId |
Burkitts lymfom i lymfeknuder i aksil og overekstremitet |
Burkitt lymphoma of lymph nodes of upper limb (disorder) |
Burkitts lymfom i lymfeknuder i lyske og underekstremitet |
Burkitt lymphoma of lymph nodes of lower limb (disorder) |
Burkitts tumor, ekstranodal OG/ELLER organlokaliseret |
Burkitt's lymphoma (clinical) |
Burkitts tumor i lymfeknuder i aksil OG/ELLER overekstremitet |
Burkitt lymphoma of lymph nodes of upper limb (disorder) |
Burkitts tumor i lymfeknuder i ingvinalregion OG/ELLER underekstremitet |
Burkitt lymphoma of lymph nodes of lower limb (disorder) |
Burn - unspecified |
Burn (disorder) |
Burn - unspecified |
Burn (disorder) |
Forbrænding af 10-14 % af legemsoverfladen, heraf 10-14 % med fuldhudsforbrænding |
Burn involving 10-19 percent of body surface, with 10-14 percent of body surface with full thickness burn (disorder) |
Forbrænding af 15-19 % af legemsoverfladen, heraf 10-19 % med fuldhudsforbrænding |
Burn involving 10-19 percent of body surface, with 15-19 percent of body surface with full thickness burn (disorder) |
Burn of cornea NOS |
Corneal burn |
Burn of cornea NOS |
Corneal burn |
Burn of eyelid NOS |
Eyelid burn |
Burn of eyelid NOS |
Eyelid burn |
Burn of internal organ NOS |
Burn of internal organ |
Burn of internal organ NOS |
Burn of internal organ |
Burn of other internal organ, NEC |
Burn of internal organ |
Burn of the trunk NOS |
Burn of trunk |
Burn of the trunk NOS |
Burn of trunk |
forbrænding på arm, ikke nærmere specificeret |
Burn of upper limb |
Burn to arm NOS |
Burn of upper limb |
Burn to cornea - erythema |
Corneal burn |
Burn to cornea - erythema |
Corneal burn |
Burn to head NOS |
Head burn (disorder) |
Burn to head NOS |
Head burn (disorder) |
Bursitis NOS |
Bursitis |
Bursit, ikke nærmere specificeret |
Bursitis |
buserelin 150 µg spray |
Buserelin only product |
Buspirone hydrochloride 5mg tablet |
Buspirone hydrochloride 5 mg oral tablet |
Buspirone hydrochlorine |
Buspirone hydrochloride (substance) |
butabarbitalnatrium 30 mg/5 ml eliksir |
Product containing precisely secbutabarbital sodium 6 milligram/1 milliliter conventional release oral solution (clinical drug) |
butorphanoltartrat 1 mg/ml injektionsvæske, opløsning, ampul |
Butorphanol tartrate 1 mg/mL solution for injection |
butorphanoltartrat 2 mg/ml injektionsvæske, opløsning, ampul |
Butorphanol only product in parenteral dose form |
Buttock random pattern flap |
Random pattern flap |
ikke-farmaceutisk butylnitrat |
Butyl nitrate |
Antipsykotisk butyrophenonderivatmiddel |
Butyrophenone derivative |
Butyrophenone poisoning NOS |
Poisoning by butyrophenone-based tranquilizer |
Bypasskomplikationer |
Complication of bypass graft |
mekaniske komplikationer til bypassoperation |
Complication of bypass graft |
Bypass graft mechanical complications |
Complication of bypass graft |
Bypass of organ NOC |
A construction of an alternate route of passage of a bodily substance |
behandling med Byrd-respirator |
Respiratory therapy |
objektiv undersøgelse fund vedr. specificeret symptom |
Finding reported by subject or history provider (finding) |
C1 esterase inhibitor 500 units powder for injection solution 8mL vial |
Product containing precisely human C1 esterase inhibitor 500 unit/1 vial powder for conventional release solution for injection (clinical drug) |
CAP - NOS |
Contraceptive cap status (finding) |
CAP - NOS |
Contraceptive cap status (finding) |
CAP used from other agency |
Contraceptive cap status (finding) |
CAP used from other agency |
Contraceptive cap status (finding) |
CAT scan - NOS |
Computed tomography (procedure) |
CDC Corynebacterium group G-1 |
Corynebacterium accolens |
CDC group DF-2 |
Capnocytophaga canimorsus |
CDE genotype |
CDE haplotype (finding) |
CDe genotype |
CDe haplotype (finding) |
CNS disorders NOS |
Disorder of the central nervous system (disorder) |
CSF appearance - NOS |
Cerebrospinal fluid appearance |
CSF cell content NOS |
Cell count, cerebrospinal fluid |
CSF chemistry - general NOS |
Determination of general chemical content of CSF |
CSF exam. - general NOS |
Determination of general chemical content of CSF |
CSF examination NOS |
Cerebrospinal fluid examination |
CSF pressure NOS |
Cerebrospinal fluid pressure |
CSF: chloride level NOS |
Cerebrospinal fluid chloride measurement (procedure) |
CSF: electrophoresis NOS |
Cerebrospinal fluid protein electrophoresis (procedure) |
CSF: globulin level NOS |
CSF globulin measurement |
CSF: microorganisms NOS |
Identification of microorganisms in cerebrospinal fluid (procedure) |
CSF: protein level NOS |
Measurement of protein in cerebrospinal fluid specimen (procedure) |
CTV3 ROOT |
SNOMED CT Concept |
CVS monitoring NOS |
Cardiovascular monitoring |
CVS monitoring NOS |
Cardiovascular monitoring |
Ca bone/joint cartilage NOS |
Malignant neoplasm of skeletal system (disorder) |
cancer i knogle/ledbrusk, ikke nærmere specificeret |
Malignant neoplasm of skeletal system (disorder) |
Ca breast - NOS |
Malignant neoplasm of breast (disorder) |
Ca breast - NOS |
Malignant neoplasm of breast (disorder) |
Ca cervix screening NOS |
Cancer cervix screening status (finding) |
Ca cervix screening NOS |
Screening for malignant neoplasm of cervix |
Ca cervix uteri NOS |
Malignant neoplasm of cervix uteri |
cancer i cervix uteri, ikke nærmere specificeret |
Malignant neoplasm of cervix uteri |
cancer i colon, ikke nærmere specificeret |
Malignant neoplasm of colon (disorder) |
Ca colon NOS |
Malignant neoplasm of colon (disorder) |
Ca esophagus NOS |
Malignant neoplasm of oesophagus |
Ca larynx - NOS |
Malignant neoplasm of larynx |
Ca larynx - NOS |
Malignant neoplasm of larynx |
Ca lip, oral, pharynx NOS |
Malignant neoplasm of lip, oral cavity and pharynx |
Ca lip, oral, pharynx NOS |
Malignant neoplasm of lip, oral cavity and pharynx |
Ca liver/biliary system NOS |
Carcinoma liver and/or biliary system (disorder) |
Ca liver/biliary system NOS |
Carcinoma liver and/or biliary system (disorder) |
Ca oesophagus NOS |
Malignant neoplasm of oesophagus |
cancer i pancreas, ikke nærmere specificeret |
Malignant neoplasm of pancreas (disorder) |
Ca pancreas NOS |
Malignant neoplasm of pancreas (disorder) |
Ca rectum + Ca anus NOS |
Malignant neoplasm of anorectum (disorder) |
cancer i rectum + cancer i anus, ikke nærmere specificeret |
Malignant neoplasm of anorectum (disorder) |
Ca skin - other NOS |
Malignant neoplasm of skin (disorder) |
Ca skin - other NOS |
Malignant neoplasm of skin (disorder) |
Ca stomach NOS |
Malignant neoplasm of stomach (disorder) |
cancer i mavesækken, ikke nærmere specificeret |
Malignant neoplasm of stomach (disorder) |
Ca uterus NOS: [carcinoma] or [cancer] |
Malignant neoplasm of uterus (disorder) |
Ca uterus NOS: [carcinoma] or [cancer] |
Malignant neoplasm of uterus (disorder) |
Cabbage - dietary |
Cabbage (substance) |
Cabergoline [parkinsons] |
Product containing cabergoline (medicinal product) |
Caesarean delivery - delivered |
Deliveries by caesarean |
Caffeine and sodium benzoate injection |
Product containing caffeine and sodium benzoate (medicinal product) |
ikke-farmaceutisk koffeinholdigt stof |
Caffeine |
Café-au-lait-pletter og ringkromosom 11 |
An autosomal anomaly with characteristics of variable clinical features, including early growth retardation and short stature, microcephaly, developmental delay, some degree of intellectual disability, facial dysmorphism and cafe-au-lait spots. In some cases, congenital heart disease and endocrine abnormalities have been reported. |